SC134-deruxtecan, a fucosyl-GM1 targeting ADC for small cell lung cancer therapy
The tumour-specific nature of FucGM1, combined with the potent SCLC killing by SC134-deruxtecan underscore the development potential of SC134 for use as an ADC therapy against SCLC.
Authors
- Dhruma Thakker
- Bubacarr G. Kaira (ORCID: https://orcid.org/0000-0003-0102-5966)
- Tina Parsons
- Ruhul Choudhury (ORCID: https://orcid.org/0000-0003-1472-9743)
- Omar J. Mohammed (ORCID: https://orcid.org/0009-0006-9025-1461)
- Mireille Vankemmelbeke (ORCID: https://orcid.org/0000-0002-8100-813X)
- Elena Dubinina (ORCID: https://orcid.org/0000-0001-5368-9970)
- Foram Dave (ORCID: https://orcid.org/0000-0002-2036-3381)
- Poonam Vaghela
- Lindy G. Durrant (ORCID: https://orcid.org/0000-0002-7217-3707)
- Bryony Heath (ORCID: https://orcid.org/0009-0005-8015-736X)
Institutions
- University of Nottingham (GB)
- Science Oxford (GB)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-08-19
- DOI
- https://doi.org/10.1186/s12967-025-06940-2
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00